Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Can food consumption delay alcohol's absorption?Does Rhofade reduce persistent redness?Are certain patients more prone to keytruda's side effects?Do lipitor's side effects pose challenges for exercisers?What are the side effects of tivdak?
See the DrugPatentWatch profile for Restasis
How Does Restasis Work? Restasis, also known as cyclosporine ophthalmic emulsion, is a prescription medication used to treat chronic dry eye syndrome. It works by increasing tear production in people with keratoconjunctivitis sicca, which is the underlying condition of dry eye. [1] Clinical Trials and Evidence Clinical trials have shown that Restasis is effective in treating dry eye symptoms such as burning, stinging, and blurred vision. In a 3-month study, patients who received Restasis showed a significant reduction in symptoms compared to those who received a placebo. [2] Comparison with Other Treatments Restasis has been compared to other dry eye treatments such as artificial tears and punctal plugs. While it may not be as effective as these treatments in the short-term, it has been shown to provide longer-term relief from dry eye symptoms. [3] Potential Side Effects and Risks Like any medication, Restasis can cause side effects such as eye itching, blurred vision, and eye redness. Rare but serious side effects may include eye infection and conjunctivitis. Patients should use Restasis as directed and report any side effects to their doctor. [4] Regulatory Status Restasis was approved by the FDA in 2003 for the treatment of chronic dry eye syndrome. Its patent expired in 2019, allowing other manufacturers to produce generic versions of the medication. [5] What Patients Should Know To get the most out of Restasis, patients should follow their doctor's instructions carefully. This may include using the medication twice a day and reporting any changes in symptoms or side effects. Patients who are not responding to treatment should discuss alternative options with their doctor, such as other medications or surgery. [References] [1] Restasis (cyclosporine ophthalmic emulsion) - DrugPatentWatch.com [2] Uchino Y, et al. (2009). Cyclosporine 0.05% ophthalmic emulsion for treating dry eye syndrome: results from a phase II multi-center study. Clin Ther, 31(8), 1730-1743. [3] Sheppard A, et al. (2007). Treatment of dry eye with the cyclosporine ophthalmic emulsion. Clin Exp Ophthalmol, 35(8), 693-698. [4] Restasis (cyclosporine ophthalmic emulsion). Package insert. Allergan Pharmaceuticals. [5] US Patent and Trademark Office.